albiglutide
Selected indexed studies
- Albiglutide. (, 2012) [PMID:31643385]
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. (Lancet, 2018) [PMID:30291013]
- Albiglutide-induced pancreatitis. (Ther Adv Drug Saf, 2016) [PMID:27904741]
_Worker-drafted node — pending editorial review._
Connections
albiglutide is a side effect of
Sources
- Albiglutide. (2012) pubmed
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. (2018) pubmed
- Albiglutide-induced pancreatitis. (2016) pubmed
- Albiglutide for the management of type 2 diabetes. (2018) pubmed
- Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases. (2024) pubmed
- Albiglutide (Tanzeum) for Diabetes Mellitus. (2017) pubmed
- Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis. (2024) pubmed
- Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide. (2017) pubmed
- Albiglutide: a unique GLP-1 receptor agonist. (2016) pubmed
- Albiglutide for the treatment of type 2 diabetes. (2014) pubmed